Demand, market for locally produced vaccines critical for sustainability of 15 COVID-19 vaccines manufacturing facilities
The history of vaccine manufacturing capacity in Africa dates back to 1881, when Egypt’s Vacsera company was established. Before the COVID-19 pandemic was declared, there were eight African countries that, to our knowledge, had a record of vaccine manufacturing facilities (see the map). They were: Algeria, Egypt, Morocco and Tunisia (North Africa); Nigeria and Senegal (West Africa); Ethiopia (East Africa); and South Africa.
Between them they had 14 facilities.
Few were involved from end to end (discovery, fill and finish, pack and distribute) production process. Instead, the focus was largely on the late stage of production process — fill and finish as well as pack and distribution.
It’s therefore not surprising that Africa’s vaccine manufacturing capacity has been limited. The facilities supply less than 1 per cent of vaccines needed for the continent.
Before the COVID-19 pandemic, efforts to address the challenge of limited vaccine production on the continent yielded little success. The pandemic clearly exposed the limited capacity to manufacture vaccines. African countries were among the last in the world to begin rolling out COVID-19 vaccines. This was largely due to limited access to vaccines and funding constraints.
As a result key stakeholders on the continent were joined by international partners, to advocate for the urgent and rapid establishment of COVID vaccines manufacturing capacity on the continent.
The urgency around manufacturing capacity
Vaccines nationalism and hoarding were topical issues in 2021. In a telling statement issued by the UN secretary general in October 2021, COVID-19 vaccines nationalism and hoarding were hampering the global response to the pandemic, putting everyone at risk of the devastating impacts of the disease, including emergence of the SARS-COV-2 variants of concern. It did not make public health sense to have a few high income countries with excess supply of COVID-19 vaccines while low income countries had nothing.
Once COVID-19 vaccines began to be approved — the first was Pfizer / BioNTech — there was high demand for rapid deployment to vaccinate 70 per cent of the global population. Demand outstripped the supply. The COVAX facility, a global collaboration to accelerate development and equitable access to COVID vaccines, was established. Despite this, high income countries used their financial muscle to secure almost all available supply of COVID-19 vaccines. Developing countries, including those on the continent, were left at the back of the queue.
African countries failed to secure the vaccines they needed. As a result, pressure began to mount on the leaders of African countries to develop local COVID vaccine manufacturing capacity.
In April 2021, the African Union Commission and Africa Centres for Disease Control hosted a two-day high-level summit to discuss the issue. The outcome of the summit was a framework for action prepared by the Partnerships for African Vaccine Manufacturing. At the same time, there were willing partners to support COVID-19 vaccine manufacturing capacity in Africa, both within Africa and outside Africa.
A logical approach to solving the problem
The logical start for the continent was to use existing vaccine manufacturing capacity. Ten of the 14 existing manufacturing facilities were front runners in launching COVID-19 vaccine production. Nine out of the 10 started production (late stages) of COVID-19 vaccines in 2021.
Encouragingly, five new facilities from five more countries (Ghana, Kenya, Uganda, Rwanda and Botswana) are being set up to produce COVID-19 vaccines. Some of the new facilities will start production of COVID-19 vaccines as early as 2022. This is an incredible achievement.
The map provides an encouraging picture and it would be tempting to say that Africa will no longer be at the back of the queue in accessing COVID vaccines. On completion of the set up of all (15) COVID-19 vaccines manufacturing facilities on the continent, Africa will be well positioned to produce other vaccines too.
A pertinent issue is the sustainability of the facilities. Demand and market for locally produced vaccines will be critical for the sustainability of the 15 COVID-19 vaccines manufacturing facilities in Africa.
There’s a salutary lesson in the example provided by Aspen Pharmacare, the South African based vaccines manufacturing plant. It was the first on the continent to enter a non-binding agreement with J&J’s Janssen to manufacture COVID vaccines.
At the time of the agreement in 2021, J&J’s COVID-19 vaccine ticked many boxes in terms of suitability for deployment on the continent. The plan was that all the vaccines manufactured at the plant would be distributed on the continent. But by May 2022, Aspen had not received orders to supply the COVID-19 vaccines to the continent, possibly due to the changing dynamics of COVID-19 vaccines supply in 2022 — supply appears to be greater than the demand.
Without demand for the vaccines, Aspen’s COVID-19 vaccines manufacturing facility is at risk of closure. Key stakeholders such as Africa CDC and the South African government have called for African countries to place orders with Aspen.
While the problem of establishing COVID-19 vaccines-manufacturing capacity appears to have been partly resolved, a bigger problem lies ahead — sustaining the facilities on the continent.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.